

Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia

Vilas Navapurkar FFICM^{*1}, Josefin Bartholdson Scott PhD^{*2}, Mailis Maes MPhil², Ellen Higginson PhD², Sally Forrest BSc², Joana Pereira-Dias MSc², Surendra Parmar MSc³, Emma Heasman-Hunt BSc³, Petra Polgarova MSc¹, Jo Brown MCLinRes¹, Lissamma Titti BN¹, William PW Smith BA⁴, Matthew Routledge MB BS⁵, David Sapsford MFRPSII⁶, Estée Török PhD^{7,8}, David Enoch FRCPath³, Vanessa Wong PhD^{3,5}, Martin D Curran PhD³, Nicholas M Brown MD³, Jurgen Herre PhD⁹, Gordon Dougan FRS², Andrew Conway Morris PhD^{1,10**}

1. John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
2. Cambridge Institute of Therapeutic Immunology & Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
3. Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
4. Clinical School, University of Cambridge, Cambridge, United Kingdom
5. Infectious Diseases, Addenbrooke's Hospital, Cambridge, United Kingdom
6. Pharmacy Department, Addenbrooke's Hospital, Cambridge, United Kingdom
7. Department of Medicine, University of Cambridge
8. Department of Microbiology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom
9. Respiratory Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom
10. Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, United Kingdom

*The identified authors contributed equally to the manuscript.

**Address for correspondence

Andrew Conway Morris
Division of Anaesthesia
Department of Medicine
Level 4, Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
Email: ac926@cam.ac.uk
Phone: +44 (0)1223 217889

Authorship (CReDIT)

VN -Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

JBS -resources, investigation, data curation, formal analysis, writing-original draft.

MM-resources, investigation, writing-review and editing.

EH-investigation, writing-review and editing.

SF-investigation, writing-review and editing.

JD-investigation, writing-review and editing.

SP-investigation, writing-review and editing.

EHH-investigation, writing-review and editing.

PP-investigation, data curation writing-review and editing.

JB-investigation, data curation writing-review and editing.

LT-investigation, data curation writing-review and editing.

WS- data curation writing-review and editing

MR-data curation writing-review and editing.

DS-data curation writing-review and editing.

ET-conceptualisation, investigation, data curation writing-review and editing

DE-investigation, writing-review and editing.

VW-formal analysis, investigation, data curation writing-review and editing.

MDC-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

NB-Conceptualisation, resources, investigation, writing-review and editing, project administration, supervision.

JH-Conceptualisation, resources, investigation, writing-review and editing.

GD-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

ACM-Conceptualisation, methodology, resources, investigation, writing-original draft, project administration, formal analysis, funding acquisition, supervision.

The study was funded by Addenbrooke's Charitable Trust and the NIHR Cambridge Biomedical Resource Centre (grant held by Professor Dougan). Dr Török is supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences and the Health Foundation) and by the NIHR Biomedical Research Centre. Dr Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z). The metagenomic sequencing was funded by the Wellcome Trust.

Declaration of interest: MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. All other authors declare no conflict of interest.

Abstract

Rationale

The diagnosis of infectious diseases has been hampered by reliance on microbial culture. Cultures take several days to return a result and organisms frequently fail to grow. In critically ill patients this leads to the use of empiric, broad-spectrum antimicrobials and compromises effective stewardship.

Objectives: To establish the performance and clinical utility of a syndromic diagnostic for severe pneumonia.

Methods

Single ICU observational cohort study with contemporaneous comparator group. We developed and implemented a TaqMan array card (TAC) covering 52 respiratory pathogens in ventilated patients with suspected pneumonia. The time to result was compared against conventional culture, and sensitivity compared to conventional microbiology and metagenomic sequencing. We observed the clinician decisions in response to array results, comparing antibiotic free days (AFD) between the study cohort and comparator group.

Results

95 patients were enrolled with 71 forming the comparator group. TAC returned results 61 hours (IQR 42-90) faster than culture. The test had an overall sensitivity of 93% (95% CI 88-97%) compared to a combined standard of conventional culture and metagenomic sequencing, with 100% sensitivity for most individual organisms. In 54% of cases the TAC results altered clinical management, with 62% of changes leading to de-escalation, 30% to an increase in spectrum, and investigations for alternative diagnoses in 9%. There was a significant difference in the distribution of AFDs with more AFDs in the TAC group ($p=0.02$).

Conclusions

Implementation of a customised syndromic diagnostic for pneumonia led to faster results, with high sensitivity and measurable impact on clinical decision making.

Keywords: Critical Care, Pneumonia, Molecular pathology, Antimicrobial stewardship

1 **Introduction**

2

3 For many decades the diagnosis of infectious diseases has relied on a combination of clinical assessment and the
4 culture of microorganisms. However, it is common for patients with clear clinical evidence of infection to have
5 negative microbiological cultures.^{1,2} Furthermore, the time taken to obtain a result by conventional culture can
6 be several days.³ Optimising antimicrobial therapy can be challenging, especially in patients who are at risk of
7 multidrug resistant organisms.² In critically ill patients, this frequently results in the empiric use of several
8 broad-spectrum agents, with predictable consequences for antimicrobial resistance and other forms of
9 antimicrobial-related harm.⁴ Conversely, failure to identify the causative organism can lead to failure to select
10 the correct antimicrobial, which is associated with poor outcomes.⁵

11

12 Pneumonia amongst ventilated, critically ill patients can be especially difficult to diagnose.⁶ Most critically ill
13 patients are systemically inflamed,⁷ clinical examination is unreliable⁸ and there are multiple causes of
14 radiographic lung infiltrates most of which are non-infectious.⁹ In the case of ventilator-associated pneumonia
15 (VAP) it is estimated that only 20-40% of patients suspected of having infection actually have it confirmed,¹⁰
16 although this confirmation relies on the imperfect diagnostic standard of microbiological culture.

17

18 The development of host-based biomarkers for infection, such as C-reactive protein,¹¹ procalcitonin,¹² and
19 alveolar cytokine concentrations¹³ have been advanced as useful measures to help rationalise antimicrobial use.
20 However, their utility in the diagnosis^{11,12} and antimicrobial stewardship^{14,15} of pneumonia has been challenged.

21

22 There is, therefore, a pressing need for rapid, sensitive, multi-pathogen focussed diagnostic tests for pneumonia
23 which can aid effective and efficient antimicrobial optimisation. The use of TaqMan array cards (TAC),
24 enabling single-plex real-time polymerase chain reaction (RT-PCR) to simultaneously target multiple respiratory
25 pathogens, has previously shown promising results compared to conventional culture methods.¹⁶ However,
26 previous experience had demonstrated that multiplex PCR with restricted coverage of common respiratory
27 pathogens had a limited impact on clinical decision making.¹⁷ In this study we set out to evaluate the clinical
28 utility of a customised TAC based syndromic diagnostic for severe pneumonia.

29

30

31

32 **Methods**

33

34 Detailed methods are included in the Supplementary appendix.

35

36 **Setting**

37 Patients were recruited from a single, 20 bedded teaching hospital Intensive Care Unit (ICU). The unit is a
38 mixed general medical-surgical unit which supports transplantation and haematology-oncology services.

39

40 **Recruitment**

41 Prospectively identified patients were eligible for inclusion if they were receiving invasive mechanical
42 ventilation, the treating clinician suspected pneumonia and was planning to perform diagnostic bronchoscopy.
43 Consent was obtained from the patient or a proxy decision maker. Patients who were not included in the study
44 due to lack of study team availability, and those from the month prior and month following the study, had their
45 data reviewed retrospectively and acted as a comparator group.

46

47 **Test development**

48 Organism coverage for the TAC was selected from the known microbial flora encountered in the ICU,
49 supplemented by the literature concerning causative organisms reported in severe pneumonia^{1,2,6, 10 17,18} The
50 species covered by the card are shown in figure 1. The card also included primers to target the endogenous
51 control RNase P and the internal control MS2, all primers were validated prior to clinical use (supplemental
52 section).

53

54 **Sampling procedure**

55 Bronchoscopy was undertaken in accordance with existing unit protocols and similar to that used in previous
56 studies.¹⁰ An ethylenediaminetetraacetic acid (EDTA) blood sample and blood culture (BACTEC, Beckton
57 Dickinson, Womersley, UK) were taken at the time of bronchoscopy.

58

59 **Conventional microbiological testing**

60 Bronchoalveolar lavage (BAL) samples were processed according to the UK Standards for Microbiology
61 Investigations (SMI).¹⁹ Further details of conventional culture and in-house multi-plex PCR assays are contained
62 in the supplemental section.

63

64 Following review by a consultant clinical scientist, results were returned to the ICU team. Clinical microbiology
65 advice was available 24 hours/day, and patients underwent daily combined ICU-Microbiology multi-disciplinary
66 review in keeping with existing unit practice. The study did not mandate any course of action by the treating
67 clinical team, however the notes were reviewed by a member of the study team to assess whether the
68 information from the TAC had influenced patient management. Conventional microbiology results were
69 returned to clinicians via the electronic health record, however in practice these were returned some time after
70 the TAC results. Data were collected on the use of antibiotics amongst patients in the study and the comparator

71 group, with the number of days alive and free of antibiotics in the seven days following lavage compared
72 (antibiotic-free days, AFDs)¹⁵.

73

74 **Metagenomic sequencing**

75 The TAC was compared to a composite reference standard of conventional bacterial culture and PCR, and
76 shotgun metagenomics, as it is recognised that culture alone is an imperfect measure of the microbial
77 composition of a sample. Details of the conventional microbiology and metagenomic sequencing are in the
78 supplemental methods.

79

80 **Economic analysis**

81 A flow model for establishing diagnostic tests and decision points for antibiotic prescribing was created (figure
82 E1). Costs for conventional microbiological tests were obtained from the Public Health England Clinical
83 Microbiology and Public Health Laboratory, whilst costs for the TAC were determined by the cost of the array
84 consumables and estimated staff time to run the assay.

85

86 **Statistical analysis**

87 The protocol, agreed prior to study initiation, set out the primary and secondary endpoints. The co-primary
88 endpoints were agreement between conventional microbiology, with sequencing added to form a composite
89 reference during the study, and the TAC, assessed by sensitivity and median time to result for conventional
90 culture and TAC assessed by Wilcoxon matched-pairs test. Where a reference standard was missing this was
91 treated as 'negative', in accordance with pessimistic assumptions about index test performance. Indeterminate
92 results were excluded from analysis. Analysis was conducted using Graphpad prism v5.0 (Graphpad inc, San
93 Diego, CA).

94

95 **Study size**

96 As the incidence of infections with specific organisms could only be inferred from conventional culture which is
97 known to be insensitive, a formal power calculation was not performed. A pragmatic study size of 100 patients
98 was selected to balance cost against including sufficient numbers to be able to make a judgement on card utility.

99

100 **Ethical and regulatory approvals and funding**

101 The study was approved by the Leeds East Research Ethics Committee (17/YH/0286) and registered with
102 clinicaltrials.gov (NCT03996330). The retrospective assessment of routinely collected data from the comparator
103 group received a consent waiver and was conducted under a protocol approved by the institutional review board
104 (A095506).

105

106

107

108

109

110 **Results**

111

112 **Initial validation**

113 To ensure cards were spotted correctly with the primers and probes in their assigned pods, nine synthetic
114 plasmids constructs containing all the target sequences were processed to quality-check each new batch of TAC
115 cards in a checker-board fashion (see supplemental section). All five microorganisms from the Quality Control
116 for Molecular Diagnostics 2018 Sepsis EQA Pilot Study were successfully detected (table E1).

117

118 **Recruitment**

119 100 patients were recruited between February 2018 and August 2019. The study flow diagram is shown in
120 figure 2. 64% of eligible patients were recruited, with lack of the study team availability the only reason for non-
121 recruitment. Table 1 shows demographic and clinical features of the study population and comparator group.

122

123 Five patients were recruited twice, having suffered a subsequent respiratory deterioration following the initial
124 episode. These episodes occurred a median of 11 days apart (range 4-42 days). In one further patient samples
125 were taken from two separate segments of the lung during the same bronchoscopic procedure. As these were
126 taken at the same time only the primary sample corresponding to the site of maximal radiographic change has
127 been included in the main results. The results of both samples are presented in table E2 for completeness.

128 Although transitory reduction in oxygenation was common during bronchoscopy, no patient in the study
129 suffered any protocol-defined serious adverse events.

130

131 **Time to result**

132 The co-primary outcome for this study was time to result for the microarray compared to validated conventional
133 microbial culture. Median difference in time to result between TAC and conventional culture was 61 hours
134 (range 19-256) (figure E2). The minimum TAC time to return was 4 hours, with median time to result 22 hours
135 (range 4-42), most of the delays in results arose from not running the card outside routine working hours.

136

137 **Comparison of organisms detected by TAC compared to conventional microbiology and sequencing.**

138 The total number of positive targets on the TAC across the 100 patients was 248 (table E3), covering 112
139 bacteria, 18 fungi and 50 viruses (table 2). The total number of negative targets was 4952 with 21 patients
140 having completely negative TAC results (table E3). To compare the card, Influenza A sub-types, HSV *glyD* and
141 *Enterococcus faecium ddl* gene targets were excluded if they were a duplicate to Flu A, HSV and *E. faecium*,
142 respectively, as was the *mecA* resistance marker as this gene was not looked for by conventional microbiology or
143 by sequencing analysis bringing the total to 226 'hits'.

144

145 Conventional microbial culture and conventional PCR were undertaken on all 100 samples, whilst metagenomic
146 sequencing was performed on residual BAL samples from 98 (two patients with suspected containment level 3
147 infection were not sequenced). Conventional microbial culture was positive for 25 organisms in 22 patients, with
148 additional 41 organisms detected by conventional PCR or *Legionella pneumophila* antigen testing in a further
149 30 patients (tables 2 and E3). A combination of shotgun and 16S amplicon sequencing approaches revealed 116

150 organisms in 72 patients (tables 2 and E3), but did not yield any significant reads for 26 patients, of which 18
151 matched the negative patients identified by TAC and conventional microbiology. In the majority of cases (51
152 samples), we observed mixed infections (table E3 and figure E3).

153

154 Taking the combined standard of conventional microbiology and sequencing, a total of 146 organisms were
155 detected, with 136 of these detected by TAC (overall sensitivity 93% 95% CI 88-97%) (table 2). 90 organisms
156 were detected by TAC only. Considering all targets, 4952 tests were negative by TAC, giving a nominal
157 specificity of 98% (95% CI 98-99%).

158

159 In terms of the 10 ‘missed organisms’, one organism, that was positive by both culture and sequencing albeit in
160 different patients, was *Citrobacter freundii*, for which we did not have a sequence on the card. A further 5
161 pathogens were detected by sequencing (*Staphylococcus aureus*, *Legionella sp.*, and *Staphylococcus*
162 *epidermidis*) or both culture and sequencing (*E. faecium* in two patients), and although detected by TAC, these
163 did not pass the internal quality control standards required for reporting and were considered ‘negative’ results.
164 The remaining three organisms, two Rhinovirus by conventional PCR and one *Staphylococcus sp* by
165 sequencing, were not detected by TAC at all. In one case the conventional culture was reported as ‘Mixed
166 respiratory tract flora at $>10^4$ CFU/ml’ with TAC detection of *E. faecium*, *C. albicans*, and *Staph. epidermidis*
167 which was deemed an indeterminate result for conventional culture, however sequencing was successful on this
168 sample.

169

170 One case of *Aspergillus fumigatus* was detected on the TAC, and although no fungal organisms were grown on
171 culture the lavage galactomannan antibody test was highly positive (5.92 Units, reference range <0.5 units), the
172 patient had radiographic evidence of fungal pneumonia and multiple risk factors for fungal infection. However,
173 two further patients met similar criteria for suspected fungal infection but were negative for aspergillus by TAC.
174 Whilst these counted as ‘true negatives’ as we had set out in our original protocol, we suggest caution in the use
175 of this card for ruling out aspergillus infection.

176

177 Notably, in the 10 samples from the 5 patients enrolled twice, the organisms detected demonstrated homogeneity
178 between samples taken within the same ICU admission (table E2), as did samples taken from two separate areas
179 of the lung on the same day.

180

181 **Quantitation**

182 In total, 25 organisms were grown on conventional culture at $\geq 10^4$ CFU/ml, the conventional cut off for
183 quantitative culture of lavage.²⁰ The median cycles to threshold (Ct) for these organisms that were also detected
184 by TAC was 27 (IQR 24-29, range 20-33). A similar range of Ct values was noted in the QCMD pilot study
185 samples (table E1).

186

187 **Comparison of conventional blood culture and TAC**

188 Nuclear material extracted from the EDTA blood sample was run on the array card. This was compared with
189 blood culture taken at the time of bronchoscopy. The yield from both conventional culture and TAC was

190 limited, with 5 positive organisms on conventional testing and 20 organisms detected on the array card (table
191 E4). *Streptococcus pneumoniae* was the only bacteria detected from blood on the array, being detected 5 times.
192 14 of the organisms were detected in both lavage and blood, including all the cases of *Streptococcus*
193 *pneumoniae* in blood.

194

195 **Impact on clinical decision making**

196 In 54 (54%) of cases the results from the TAC led to a change in management of the patients (table 3). 34 (63%)
197 of these decisions involved decrease in antimicrobial intensity, whilst 17 (31%) involved broadening of the
198 spectrum of coverage and in five cases the result prompted a search for an alternative diagnosis (two also
199 involved de-escalation of antimicrobials). In some patients several changes occurred. In a further five cases the
200 research team's opinion was that management could have been changed (all five cases would have been de-
201 escalation). Patients in the comparator group demonstrated fewer days alive without antibiotics (distribution of
202 AFDs shown in figure 3).

203

204 **Economic analysis**

205 The costs of conventional microbiological testing were £222 (US\$ 286), whilst the costs of TAC and
206 bacteriological culture for sensitivity testing was £171 (US\$ 220), a difference of £51 (US\$65). Figure E1 shows
207 workflow with and without TAC.

208

209

210 **Discussion**

211

212 In this study we demonstrate that a customised molecular diagnostic, designed to meet the needs of a specific
213 clinical setting produced accurate results in a clinically important timeframe and influenced patient management
214 decisions. This was within the context of a well-established antimicrobial stewardship programme. Results
215 were returned to clinicians 61 hours faster than conventional cultures, and the accuracy of the results was
216 confirmed by culture, sequencing or both. Notably, many previous studies in respiratory infection specifically
217 exclude critically ill patients, who are those who may suffer the most from inappropriate antimicrobial therapy⁵
218 but are also at greatest risk of antimicrobial-associated harm.⁴ Importantly this can be achieved at no additional
219 cost to the laboratory.

220

221 Molecular diagnostic platforms for respiratory infection syndromes have, until recently, largely focussed on
222 viral pathogens. Whilst distinguishing viral from bacterial infection can be helpful in managing uncomplicated
223 infection, the frequent occurrence of bacterial co-infection in hospitalised patients¹⁸ and the need to optimise
224 antimicrobial therapy whilst limiting the over-use of these precious drugs has led to repeated calls for effective
225 bacterial-focussed diagnostics.²¹ TACs have been previously reported for use in pneumonia.^{17,22, 23} However
226 ,apart from our previous report¹⁷ that demonstrated limited clinical impact due to restricted organism coverage,
227 none of the other reports have included ventilated patients and all were restricted to retrospective analysis of
228 stored samples. Commercial multiple-pathogen arrays that include respiratory bacteria have recently become
229 available, however reports of their use in ventilated patients also remain restricted to retrospective analysis of

230 stored samples,^{3,24,25} and these assays lack the breadth of coverage and the customisability of the TAC. One
231 report commented that use of the commercial assay investigated to withhold antibiotics could have led to
232 inappropriate undertreatment.³

233

234 Patients who develop critical illness as a result of pneumonia present a particular diagnostic challenge, as these
235 infections may involve a variety of bacterial, fungal and viral pathogens.² Although the source of acquisition of
236 severe pneumonia may indicate the risk of particular organisms,^{6,26,27} this is an imperfect method of predicting
237 the causative organism.²⁸ The difficulty in predicting the causative organism, coupled with the insensitivity of
238 growth-based culture detection leads to frequent use of multiple, broad-spectrum antimicrobials. Even when
239 culture results in growth of an organism, the time-frame on which these results are available compromises
240 effective antimicrobial stewardship, and in practice de-escalation is rare²⁹ as there remains a constant concern
241 about organisms which remain undetected.

242

243 Although there is now widespread acceptance of the presence of a respiratory microbiome,^{30,31} the lungs of
244 ventilated patients present a challenge to highly sensitive molecular diagnostics. The proximal respiratory tract
245 of ventilated patients becomes rapidly colonised with predominantly Gram negative organisms³² as the
246 microbiome is disrupted.^{31,33} This can occur in the absence of infection, and there is a risk that highly sensitive
247 techniques will be more susceptible to the detection of colonising organisms, driving an unintended increase in
248 antimicrobial use. The use of quantitative cultures and protected lower airways specimens has been advocated
249 as ways of distinguishing infection from colonisation.^{20,34} We adapted this approach in this study, using the
250 quasi-quantitative Ct value provided by RT-PCR and testing protected broncho-alveolar samples. This ensured
251 that the dominant change in practice seen was the de-escalation of antimicrobials. However, although almost all
252 studies of molecular diagnostics focus on reduction in antimicrobial use^{15,35} we found a substantial proportion of
253 changes involved broadening the coverage through escalation or addition to cover organisms that had not been
254 anticipated. Had our study been judged by conventional ‘reduction in antimicrobial use’ the modest reduction in
255 antibiotic-free days seen may have been considered irrelevant. We suggest that consensus measures of
256 antimicrobial optimization be developed to assess the clinical utility of novel microbial diagnostics.

257

258 One of the problems that has beset microbial diagnostics studies has been the absence of a ‘gold standard’
259 against which the candidate can be assessed,³⁵ as it is acknowledged that conventional culture is imperfect. For
260 this study we developed a new composite ‘confirmation standard’, using both conventional culture and
261 metagenomic sequencing. In all but 10 cases, organisms identified by conventional microbiology or sequencing
262 were detected by the TAC. The card was, overall, more sensitive than either of the confirmatory techniques.
263 We do not believe these additional TAC hits to be true ‘false positives’ but rather reflect the enhanced sensitivity
264 of targeted PCR. Notably, all of these TAC-only detections occurred at high Ct values, indicating limited and
265 almost certainly clinically irrelevant numbers of organisms. We therefore believe that the sequencing and
266 culture results can give clinicians considerable confidence in the results provided.

267

268 The selection of organisms targeted on the card was crucial, and informed by our previous experience where
269 omission of key organisms of concern significantly limited the impact of a similar card.¹⁷ Given the case mix of

270 our unit, with a high proportion of immunosuppressed patients, we opted to include a number of low
271 pathogenicity organisms, such a coagulase-negative *Staphylococci*, *Enterococci* and *Candida albicans* on the
272 card. The detection of these organisms can be challenging to interpret, and indeed given the knowledge that
273 many critically ill patients may be immunoparietic even if not classically immunosuppressed⁶ their significance
274 remains uncertain. Their presence, and the frequency of polymicrobial detection, indicates a dysbiotic response
275 in the lungs of critically ill patients,^{31,33,34,36} and knowing how to respond to this dysbiosis remains an area of
276 uncertainty. One of the advantages of the TAC as a platform is its customizability, and single targets can be
277 easily added or modified without having to re-optimize the entire panel, which would also allow it to be adapted
278 to other units or rapidly modified to deal with an emerging infectious threat.

279

280 This study had a number of strengths. We developed a test that met the needs of a particular unit, and
281 implemented it in the context of a well-established stewardship programme. We managed to include a
282 significant proportion of the patients undergoing bronchoscopic investigation for pneumonia, and thus our
283 results are likely to be representative of our unit's workload. As an observational study, the assessment of
284 impact on clinical decision making is susceptible to bias, and we cannot be sure that the changes to clinical
285 management made would not have occurred without the TAC result. However, the more objective increase in
286 AFDs relative to the comparator group is supportive of genuine impact. Our comparator group was similar to
287 the study group, and by being drawn from the same time period of the study being managed by the same
288 clinicians, in an environment in which a study which may influence antimicrobial stewardship was occurring,
289 therefore we believe the differences seen are indeed due to the diagnostic approach used. Even when clinicians
290 are presented with a validated, accurate test, achieving a change in prescribing practice is challenging¹⁵

291

292 In conclusion, we have developed a customised respiratory diagnostic which covers a broad range of pathogenic
293 organisms, and validated it using a combination of culture, PCR and sequencing. In a pragmatic, observational
294 study of the implementation of this tool we were able to see significant impact on clinical decision making. We
295 believe this represents a significant advance in the diagnostics of severe pneumonia, and have adopted this
296 technology across our hospital for the investigation of such patients.

297

298

299

300

301

302

303 Acknowledgements

304

305 The authors thank the consultant intensivists of the John V Farman Intensive Care Unit, Drs P Bradley, P
306 Featherstone, S Ford, M Georgieva, A Johnston, R Mahroof, J Martin, J Preller, K Patel, C Summers M
307 Trivedi, J Varley, Pharmacist L Radford and the nursing and physiotherapy teams who managed the patients,
308 and the patients and their families who consented to the study. We also thank Torsten Seemann for access to his
309 Kraken database.

310

311

312

313

314

315

316
317
318
319
320
321
322
323
324

325 **References:**

326
327
328

1. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax*. 2011;66(4):340-346.

329
330

2. Vincent J-L, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA*. 2020;323(15):1478–10.

331
332
333
334

3. Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. *Eur J Clin Microbiol Infect Dis*. 2019;38(6):1171–1178.

335
336

4. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Morris AC. Antimicrobial-associated harm in critical care: a narrative review. *Intensive Care Med*. January 2020:1-11.

337
338
339

5. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. 2002;122(1):262-268.

340
341

6. Morris AC. Management of pneumonia in intensive care. *J Emerg Crit Care Med*. 2018;2(0):101-101.

342
343

7. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The Natural History of the Systemic Inflammatory Response Syndrome (SIRS). *JAMA*. 1995;273(2):117–5.

344
345
346

8. Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby J-J. Comparative diagnostic performances of auscultation, chest radiography, and lung ultrasonography in acute respiratory distress syndrome. *Anesthesiology*. 2004;100(1):9-15.

347
348

9. Meduri GU, Mauldin GL, Wunderink RG, et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. *Chest*. 1994;106(1):221-235.

349
350

10. Conway Morris A, Kefala K, Wilkinson TS, et al. Diagnostic importance of pulmonary interleukin-1 {beta} and interleukin-8 in ventilator-associated pneumonia. *Thorax*. 2010;65(3):201-207.

351
352

11. Povoia P, Coelho L, Almeida E, et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. *Eur Resp J*. 2005;25(5):804-812.

353
354
355

12. Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. *Critical Care*. 2014;18(2):1-11.

356
357

13. Hellyer TP, Morris AC, Mcauley DF, et al. Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia. *Thorax*. 2015;70(1):41-47.

358
359

14. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. *N Engl J Med*. 2018;379(3):236-249.

- 360 15. Hellyer TP, McAuley DF, Walsh TS, et al. Biomarker-guided antibiotic stewardship in
361 suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process
362 evaluation. *Lancet Resp Med*. December 2019:1-10.
- 363 16. Steensels D, Reynders M, Descheemaeker P, et al. Clinical evaluation of a multi-parameter
364 customized respiratory TaqMan® array card compared to conventional methods in
365 immunocompromised patients. *J Clin Virol*. 2015;72:36-41.
- 366 17. Jones N, Conway Morris A, Curran MD et al. Evaluating the use of a 22-pathogen TaqMan
367 array card for rapid diagnosis of respiratory pathogens in Intensive Care. *J Med Micro*. in press.
- 368 18. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for
369 Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis*. 2016;62(7):817-823.
- 370 19. Public Health England. Investigation of bronchoalveolar lavage, sputum and associated
371 specimens UK SMI B 57 issue 3.5 (May 2019) (available from
372 [https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-](https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens)
373 [sputum-and-associated-specimens](https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens)) accessed 20/5/2020
- 374 20. Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for the surveillance of
375 healthcare-associated infections in intensive care units. *Intensive Care Med*. October 2018:1-3.
- 376 21. The Lancet Respiratory Medicine. Pneumonia research: time to fill in the gaps. *Lancet Resp*
377 *Med*. 2019;7(12):993.
- 378 22. Wolff BJ, Bramley AM, Thurman KA, et al. Improved Detection of Respiratory Pathogens by
379 Use of High-Quality Sputum with TaqMan Array Card Technology. Onderdonk AB, ed. *J Clin*
380 *Microbiol*. 2017;55(1):110-121.
- 381 23. Hercik C, Cosmas L, Mogeni OD, et al. A diagnostic and epidemiologic investigation of acute
382 febrile illness (AFI) in Kilombero, Tanzania. Schildgen O, ed. *PLoS ONE*. 2017;12(12):e0189712-
383 e0189720.
- 384 24. Pulido MR, Moreno-Martínez P, González-Galán V, et al. Application of BioFire FilmArray
385 Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated
386 pneumonia. *Clini Micro Infect*. 2018;24(11):1213.e1-1213.e4.
- 387 25. Yoo IY, Huh K, Shim HJ, et al. Evaluation of the BioFire FilmArray Pneumonia Panel for
388 rapid detection of respiratory bacterial pathogens and antibiotic resistance genes in sputum and
389 endotracheal aspirate specimens. *Int J Infect Dis*. 2020;95:326-331.
- 390 26. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the
391 management of adults with hospital-acquired, ventilator-associated, and healthcare-associated
392 pneumonia. *Am J Respir Crit Care Med*. 2005;171(4):388-416.
- 393 27. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. *Am J Respir Crit Care Med*.
394 2002;165(7):867-903.
- 395 28. Yap V, Datta D, Metersky ML. Is the Present Definition of Health Care–Associated
396 Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens? *Infect Dis*
397 *Clin North Am*. 2013;27(1):1-18.
- 398 29. Kollef MH, Morrow LE, Niederman MS, et al. Clinical Characteristics and Treatment Patterns
399 Among Patients With Ventilator-Associated Pneumonia. *Chest*. 2006;129(5):1210-1218.
- 400 30. Langelier C, Kalantar KL, Moazed F, et al. Integrating host response and unbiased microbe
401 detection for lower respiratory tract infection diagnosis in critically ill adults. *Proc Natl Acad Sci USA*.
402 2018;319:201809700.

- 403 31. Zakharkina T, Martin-Loeches I, Matamoros S, et al. The dynamics of the pulmonary
404 microbiome during mechanical ventilation in the intensive care unit and the association with occurrence
405 of pneumonia. *Thorax*. 2017;72(9):803-810.
- 406 32. Ewig S, Torres A, El-Ebiary M, et al. Bacterial colonization patterns in mechanically
407 ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with
408 ventilator-associated pneumonia. *Am J Respir Crit Care Med*. 1999;159(1):188-198.
- 409 33. Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of respiratory dysbiosis
410 in hospital-acquired pneumonia. *Lancet Resp Med*. 2019;7(8):710-720.
- 411 34. Morris AC, Kefala K, Simpson AJ, et al. Evaluation of the effect of diagnostic methodology
412 on the reported incidence of ventilator-associated pneumonia. *Thorax*. 2009;64(6):516-522.
413 doi:10.1136/thx.2008.110239.
- 414 35. Bhat N, O'Brien KL, Karron RA, Driscoll AJ, Murdoch DR, the Pneumonia Methods Working
415 Group. Use and Evaluation of Molecular Diagnostics for Pneumonia Etiology Studies. *Clin Infect Dis*.
416 2012;54(suppl 2):S153-S158.
- 417 36. Nolan TJ, Gadsby NJ, Hellyer TP, et al. Low-pathogenicity *Mycoplasma* spp. alter human
418 monocyte and macrophage function and are highly prevalent among patients with ventilator-acquired
419 pneumonia. *Thorax*. 2016;71(7):594-600.
- 420

421

Parameter	Study patients (95 patients)	Comparator group (71 patients)
Median age (range)	60 (21-86)	62 (18-83)
n(%) female	41 (43 %)	27 (38 %)
Median functional comorbidity index	1 (2)	-
% with community-acquired Hospital-acquired (of which ventilator-associated)	36% 64% (39%)	28% 72% (52%)
Median (IQR) APACHE II score on admission	16 (10)	16 (9)
% receiving antibiotics at time of lavage	82%	96%
Median (IQR) FiO2 prior to bronchoscopy	0.5 (0.25)	0.5 (0.30)
Median (IQR) white cell count	10.5 (12.4)	10.7 (9.5)
Median (IQR) neutrophil count	8.6 (11.5)	8.8 (8.63)
Median (IQR) C-reactive protein concentration	198 (153)	146 (154)
28 day Mortality	30 (32%)	21 (30%)

422

423

424

425

426

427

Table 1: clinical and demographic details of patients enrolled in the study. APACHE II, acute physiology and chronic health evaluation II, FiO2, fraction of inspired oxygen.

428

Organism detected	Frequency (by conventional microbiology)	Frequency (by TAC)	Frequency (by sequencing)
Bacteria			
<i>Citrobacter freundii</i>	1	0	1***
<i>Enterobacter cloacae</i>	1	8	3
<i>Enterobacter sp. (not further specified)</i>	1	0	2
<i>Enterococcus faecalis</i>	0	3	0
<i>Enterococcus faecium</i>	3	7	6
<i>Enterococcus sp. (not further specified)</i>	0	0	2
<i>Escherichia coli</i>	6	14	6
<i>Klebsiella pneumoniae</i>	3	5	3
<i>Enterobacteriaceae (not further specified)</i>	0	2	6
<i>Haemophilus influenzae</i>	0	3	2
<i>Legionella pneumophila</i>	0*	1	1
<i>Legionella sp. (non-pneumophila)</i>	0	2	2
<i>Moraxella catharralis</i>	0	1	0
<i>Mycoplasma pneumoniae</i>	0	1	1
<i>Proteus sp.</i>	0	2	0
<i>Pseudomonas aeruginosa</i>	2	5	4
<i>Serratia marcescens</i>	1	3	0
<i>Staphylococcus aureus</i>	2	8	8
<i>Staphylococcus epidermidis</i>	0	9	2
Other coagulase negative <i>Staphylococcus</i>	0	1	2
<i>Stenotrophomonas maltophilia</i>	2	4	2
<i>Streptococcus pneumoniae</i>	1	9	6
<i>Streptococcus pyogenes</i>	0	1	0
<i>Streptococcus sp.</i>	0	23	10
Mixed upper respiratory tract flora	1	N/A	N/A
Fungi			
<i>Aspergillus spp.</i>	0**	1	0
<i>Candida albicans</i>	1	12	10
<i>Candida spp.</i>	0	1	1
<i>Pneumocystis jirovecii</i>	4	4	4***
Viruses			
Coronavirus	0	3	1
Cytomegalovirus	3	7	4
Epstein-Barr Virus	1	6	1
Herpes simplex virus	7	11	7
Human metapneumovirus	1	1	1
Influenza A	7	7	5
Influenza B	3	3	2
Parainfluenza virus	4	4	4
Rhinovirus	8	8	7

429

430

431

432

433

434

435

436

437

438

439

440

Table 2: Organisms detected by conventional microbiological testing (left hand column), by TAC (middle column), and by microbial sequencing (right hand column). * Legionella urinary antigen test positive. ** Positive BAL galactomannan enzyme immunoassay (>0.5 units) with CT consistent with fungal pneumonia and known risk factors but fungal cultures were not positive. ***One hit not found in same patient.

Type of change		
Reduction in spectrum	Stopping therapeutic antimicrobial agent(s)*	24
	Changing to a narrower spectrum	9
	Withholding planned treatment	2
Increase in spectrum	Addition of further antimicrobials	10
	Change to broader spectrum agent	8
Alternative diagnosis investigated or made	Computed Tomography scan	2
	Tissue biopsy	2
	Alternative diagnosis made	2

441
442
443
444
445
446
447

Table 3: changes in treatment made as a result of findings from the TAC (some patients had more than one change within a given type – e.g. both reduction spectrum and cessation of antimicrobials) .

*in two cases antimicrobials were reduced to prophylactic dose as patients remained at risk of opportunistic infections

448




Figure 1: layout of TAC


449

450

451


452

453



454
455
456
457
458
459

Figure 2: recruitment flow chart



460
461
462
463
464

Figure 3: Distribution of days alive and free of antibiotics in the seven days following bronchoscopy and lavage in the TAC and comparator cohorts. Following first lavage only for patients who had more than one BAL during ICU admission. Numbers in each category and percentage shown below graph, p value by Mann-Whitney U test.

